Study on the Evaluation of Coagulation Characteristics in Patients with Gastrointestinal Malignancies by Thrombotic Molecular Markers

This study examines the coagulation function characteristics of patients with gastrointestinal malignancies. By comparing the levels of coagulation molecular markers in 215 patients with gastrointestinal malignancies (the case group) and 1 16 healthy controls, it was found that the levels of thrombin-antithrombin complex (TAT) and plasmin-α2-fibrin inhibitor complex (PIC) were significantly elevated in the case group (P<0.001). The t-PAIC level in gastric cancer patients differed from that in colorectal cancer patients (P<0.05), with higher levels in colorectal cancer patients compared to gastric cancer patients. There was no significant difference in thrombotic molecular markers across different tumor stages. The risk score for venous thromboembolism (VTE) increased, and the TM showed a gradient increase. This suggests that coagulation abnormalities may occur early in gastrointestinal malignancies, and as the risk of VTE increases, there is significant endothelial damage, with coagulation molecular marker levels being associated with tumor type and VTE risk.